Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial

BACKGROUND: Cabazitaxel significantly improves overall survival (OS) versus mitoxantrone in patients with metastatic castration-resistant prostate cancer after docetaxel failure. We examined patient survival at 2 years and tumour-related pain with cabazitaxel versus mitoxantrone. METHODS: Updated TR...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Bahl, A., Oudard, S., Tombal, B., Özgüroĝlu, M., Hansen, S., Kocak, I., Gravis, G., Devin, J., Shen, L., de Bono, J. S., Sartor, A. O.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2013
Onderwerpen:
Original Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3755329/
https://ncbi.nlm.nih.gov/pubmed/23723295
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt194
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items